Results 1 to 10 of about 42,523 (291)
Interacti on of buprenorphine with phosphatidylcholine [PDF]
Thermochimica Acta, 1989 The interaction between phosphatidylcholine and buprenorphine have been studied by means of differential scanning calorimetry of liposome, compression isotherms and penetration kinetics of monolayers. The results show that the interactions are highly dependent on the ionized state of the buprenorphine molecules, being higher in buffered solutions.
F. Reig +5 more
openalex +4 more sources
Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men [PDF]
Addiction and Health, 2018 Background: Buprenorphine sublingual tablets are now available in Iran for opioid detoxification in clinics. Aim of the present study was to compare the efficiency of buprenorphine with buprenorphine/naloxone in short-term detoxification in a group of ...
Hassan Ziaaddini +4 more
doaj +4 more sources
Managing opioid withdrawal precipitated by buprenorphine with buprenorphine [PDF]
Drug and Alcohol Review, 2021 AbstractBuprenorphine is a partial opioid agonist commonly used to treat opioid dependence. The pharmacology of buprenorphine increases the risk of a precipitated opioid withdrawal when commencing patients on buprenorphine treatment, particularly when transferring from long acting opioids (e.g. methadone).
Bridget Oakley +3 more
openaire +3 more sources
Buprenorphine and temazepam—abuse [PDF]
British Journal of Addiction, 1990 Richard Hammersley +2 more
openalex +4 more sources
Acta Crystallographica Section E Structure Reports Online, 2014 In the crystal structure of a semi-synthetic opioid drug buprenorphine, C29H41NO4{systematic name: (2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-3-hydroxy-6-methoxy-4,5-epoxy-6,14-ethanomorphinan-7-yl]-3,3-dimethylbutan-2-ol}, the cyclopropylmethyl group is disordered over two sites with an occupancy factor of 0.611 (3) for the major component.
Jaroslaw Mazurek +4 more
openaire +3 more sources
Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study
Harm Reduction Journal, 2023 Background Recent policies have lessened restrictions around prescribing buprenorphine-naloxone (buprenorphine) for the treatment of opioid use disorder (OUD).
Joëlla W. Adams +5 more
doaj +1 more source
JA Clinical Reports, 2022 Background We tested the hypothesis that patients who continued buprenorphine postoperatively experience postoperative respiratory depression less frequently than those who discontinued buprenorphine.
Ryu Komatsu +5 more
doaj +1 more source
Harm Reduction Journal, 2022 Background Syringe services programs (SSPs) hold promise for providing buprenorphine treatment access to people with opioid use disorder (OUD) who are reluctant to seek care elsewhere.
Andrea Jakubowski +8 more
doaj +1 more source
Frontiers in Psychiatry, 2022 Buprenorphine, which has been approved for the treatment of opioid dependence, reduces cocaine consumption by co-activating μ-opioid receptors and nociceptin/orphanin FQ peptide (NOP) receptors. However, the role of buprenorphine in methamphetamine (METH)
Fangmin Wang +11 more
doaj +1 more source